ClearPoint Neuro, Inc.

Equities

CLPT

US18507C1036

Advanced Medical Equipment & Technology

Market Closed - Nasdaq Other stock markets 21:00:00 23/05/2024 BST			5-day change	1st Jan Change
6.21 ^USD	+2.48%		-2.97%	-8.54%

05-07	ClearPoint Neuro, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
05-07	Earnings Flash (CLPT) CLEARPOINT NEURO Reports Q1 Revenue $7.6M, vs. Street Est of $7M	MT

ClearPoint Neuro, Inc. Announces Appointment of Ellisa Cholapranee as General Counsel, Effective April 5, 2021

March 24, 2021 at 08:05 pm

ClearPoint Neuro, Inc. announced that Ellisa Cholapranee will join the Company as General Counsel on April 5, 2021. Ms. Cholapranee will report directly to Joe Burnett, ClearPoint Neuro’s Chief Executive Officer, and serve as a member of the Company’s senior leadership team.

Latest news about ClearPoint Neuro, Inc.

ClearPoint Neuro, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-07	CI
Earnings Flash (CLPT) CLEARPOINT NEURO Reports Q1 Revenue $7.6M, vs. Street Est of $7M	05-07	MT
Transcript : ClearPoint Neuro, Inc., Q1 2024 Earnings Call, May 07, 2024	05-07
Clinical Laserthermia Notes US FDA Clearance for ClearPoint's Prism Bone Anchor Accessory	04-30	MT
ClearPoint Gets FDA Clearance For Neurosurgical Equipment	04-29	MT
ClearPoint Neuro, Inc. Announces FDA Clearance of Prism Bone Anchor Accessory	04-29	CI
ClearPoint Neuro, Inc. Announces Initiation of Limited Market Release for the SmartFrame OR? Stereotactic System	04-24	CI
ClearPoint Neuro Says Partner AviadoBio Treats First Person in Trial of AVB-101 for Frontotemporal Dementia	04-16	MT
Stifel Adjusts Price Target on ClearPoint Neuro to $9 From $8, Maintains Buy Rating	03-13	MT
ClearPoint Neuro, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-12	CI
Transcript : ClearPoint Neuro, Inc., Q4 2023 Earnings Call, Mar 12, 2024	03-12
Earnings Flash (CLPT) CLEARPOINT NEURO Posts Q4 Revenue $6.8M, vs. Street Est of $6.5M	03-12	MT
ClearPoint Neuro, Inc. Reaffirms Revenue Guidance for the Year 2024	03-12	CI
ClearPoint Neuro, Inc. Announces Preclinical Results of an in Vivo Validation Study Have Been Published in the Journal of Neurosurgery	03-11	CI
ClearPoint Neuro to Seek Acquisitions	03-01	CI
ClearPoint Neuro, Inc. Announces FDA Clearance and First-In-Human Cases Performed with the New 2.2 Software Version and the Integrated Maestro Brain Model	02-21	CI
ClearPoint Neuro, Inc. Announces Installation and First Procedure Using the Clearpoint Prism® Neuro Laser Therapy System and Navigation System At Kaleida Health in Buffalo	01-24	CI
Clearpoint Neuro Receives 510(K) Clearance for Smartframe or Stereotactic System	01-16	CI
ClearPoint Neuro Shares Up 16% After Prelim. 4Q Revenue Beats Estimates	01-09	DJ
Clinical Laserthermia Systems Gets SEK8 Million Order from ClearPoint Neuro; Stocks Rise	01-09	MT
ClearPoint Neuro, Inc. Provides Revenue Guidance for the Full Year 2024	01-08	CI
Lake Street Cuts ClearPoint Neuro Price Target to $11 From $15, Maintains Buy Rating	11-10	MT
ClearPoint Neuro, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09	CI
Transcript : ClearPoint Neuro, Inc., Q3 2023 Earnings Call, Nov 09, 2023	11-09
Earnings Flash (CLPT) CLEARPOINT NEURO Reports Q3 Revenue $5.8M, vs. Street Est of $6.73M	11-09	MT

Chart ClearPoint Neuro, Inc.

Duration

Period

More charts

Company Profile

ClearPoint Neuro, Inc. is a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine. The Company provides both clinical products as well as pre-clinical development services for controlled drug and device delivery. The Companyâs flagship product is the ClearPoint Neuro Navigation System. Its initial product offering, the ClearPoint system, is an integrated system comprised of capital equipment and disposable products, designed to allow minimally invasive procedures in the brain to be performed in a magnetic resonance imaging (MRI) suite. The ClearPoint Array Neuro Navigation System and its principal disposable component is designed to be deployed in an operating room setting while also being usable in an MRI suite. It is engaged with healthcare and research centers in North America, Europe, Asia, and South America. It also provides solutions for direct CNS delivery of therapeutics in pre-clinical studies and clinical trials worldwide.

Sector

Advanced Medical Equipment & Technology

Calendar

05/08/2024 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for ClearPoint Neuro, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

6.21 USD

Average target price

10 USD

Spread / Average Target

+61.03%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Advanced Medical Equipment & Technology

	1st Jan change	Capi.
CLEARPOINT NEURO, INC.	-8.54%	170M
THERMO FISHER SCIENTIFIC	+10.22%	223B
DANAHER CORPORATION	+12.99%	194B
INTUITIVE SURGICAL, INC.	+18.09%	141B
BOSTON SCIENTIFIC CORPORATION	+28.66%	109B
SIEMENS HEALTHINEERS AG	+1.86%	64.85B
EDWARDS LIFESCIENCES CORPORATION	+14.70%	52.7B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	+6.68%	51.77B
AGILENT TECHNOLOGIES, INC.	+8.29%	44.12B
GE HEALTHCARE TECHNOLOGIES INC.	+2.60%	36.21B

Other Advanced Medical Equipment & Technology